A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

Saved in:
Bibliographic Details
Published inBlood cancer journal (New York) Vol. 11; no. 5; pp. 89 - 5
Main Authors Mikhael, Joseph, Belhadj-Merzoug, Karim, Hulin, Cyrille, Vincent, Laure, Moreau, Philippe, Gasparetto, Cristina, Pour, Ludek, Spicka, Ivan, Vij, Ravi, Zonder, Jeffrey, Atanackovic, Djordje, Gabrail, Nashat, Martin, Thomas G., Perrot, Aurore, Bensfia, Samira, Weng, Qilong, Brillac, Claire, Semiond, Dorothée, Macé, Sandrine, Corzo, Kathryn P., Leleu, Xavier
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 12.05.2021
Springer Nature B.V
Nature Publishing Group
Subjects
692/308/153
692/699/1541/1990/804
Aged
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents, Immunological - adverse effects
Antineoplastic Agents, Immunological - therapeutic use
Biomedical and Life Sciences
Biomedicine
Cancer Research
Correspondence
Drug Resistance, Neoplasm
Female
Hematology
Humans
Male
Middle Aged
Multiple Myeloma - drug therapy
Oncology
Treatment Outcome
Online AccessGet full text

Cover

More Information
ISSN:2044-5385
2044-5385
DOI:10.1038/s41408-021-00478-4